European Lung Cancer Conference (ELCC) 2025 Highlights: KEYNOTE-799, LAURA, MARIPOSA, KRYSTAL-7

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025.

We dived into several key studies that are shaping the future of lung cancer treatment, including:
• KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC).
• LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy.
• MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC.
• KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy.

Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies.

YouTube: https://youtu.be/akoXXAUEl_8

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!

#Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast